Taken together, our in vivo studies mirror our in vitro findings and show that MD2 inhibitor L6H21 exhibits greater inhibitory activities on colon tumors by targeting MD2 and its downstream signaling components. This evidence concerns the gene LY96 and colonic neoplasm.